• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞病毒UL97激酶基因第591至603密码子突变所赋予的更昔洛韦耐药性的不同水平

Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.

作者信息

Chou Sunwen, Ercolani Ronald J, Vanarsdall Adam L

机构信息

Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA

VA Medical Center, Portland, Oregon, USA.

出版信息

J Clin Microbiol. 2017 Jul;55(7):2098-2104. doi: 10.1128/JCM.00391-17. Epub 2017 Apr 26.

DOI:10.1128/JCM.00391-17
PMID:28446569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5483911/
Abstract

Diagnostic mutations in the cytomegalovirus UL97 kinase gene are used to assess the level of associated ganciclovir resistance and therapeutic options. The best-known mutations at codons 460, 520, or 591 to 607 individually confer 5- to 10-fold-decreased ganciclovir susceptibility, except that a 3-fold decrease occurs in the case of the amino acid substitution C592G. Less common point and in-frame deletion mutations at codons 591 to 603 remain incompletely characterized. The ganciclovir susceptibilities of 17 mutants in this codon range were evaluated by use of the same recombinant phenotyping system and extensive assay replicates in two types of cell cultures. Amino acid substitutions K599E and T601M conferred no ganciclovir resistance, while A591V conferred 3.8-fold-decreased susceptibility. In-frame deletions of three or more codons conferred at least 8-fold-increased ganciclovir resistance, while the level of resistance conferred by one- or two-codon deletions varied from 4- to 10-fold, depending on their location. Measured levels of ganciclovir resistance were closely comparable when assays were performed in either fibroblasts or modified retinal epithelial cells. The significant revision of a few previously published resistance phenotypes and the new data strengthen the interpretation of genotypic testing for cytomegalovirus drug resistance.

摘要

巨细胞病毒UL97激酶基因中的诊断性突变用于评估相关的更昔洛韦耐药水平和治疗选择。密码子460、520或591至607处最著名的突变分别使更昔洛韦敏感性降低5至10倍,但氨基酸替代C592G的情况会使敏感性降低3倍。密码子591至603处较罕见的点突变和框内缺失突变的特征仍不完全清楚。通过使用相同的重组表型分析系统,并在两种类型的细胞培养物中进行大量的分析重复,评估了该密码子范围内17个突变体的更昔洛韦敏感性。氨基酸替代K599E和T601M不赋予更昔洛韦耐药性,而A591V使敏感性降低3.8倍。三个或更多密码子的框内缺失使更昔洛韦耐药性至少增加8倍,而一或两个密码子缺失所赋予的耐药水平根据其位置在4至10倍之间变化。在成纤维细胞或改良的视网膜上皮细胞中进行检测时,所测得的更昔洛韦耐药水平密切可比。对一些先前发表的耐药表型的重大修订以及新数据加强了对巨细胞病毒耐药性基因检测的解释。

相似文献

1
Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene.巨细胞病毒UL97激酶基因第591至603密码子突变所赋予的更昔洛韦耐药性的不同水平
J Clin Microbiol. 2017 Jul;55(7):2098-2104. doi: 10.1128/JCM.00391-17. Epub 2017 Apr 26.
2
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.影响对更昔洛韦敏感性的巨细胞病毒UL97磷酸转移酶突变
J Infect Dis. 2002 Jan 15;185(2):162-9. doi: 10.1086/338362. Epub 2001 Dec 17.
3
Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing.通过扩展基因型检测发现巨细胞病毒 UL97 ATP 结合区域突变的更昔洛韦和马拉韦罗敏感性表型。
Antiviral Res. 2021 Sep;193:105139. doi: 10.1016/j.antiviral.2021.105139. Epub 2021 Jul 14.
4
Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene.两种 UL97 基因 466 密码子突变对更昔洛韦敏感性和复制能力的对比影响。
J Clin Virol. 2010 Dec;49(4):296-8. doi: 10.1016/j.jcv.2010.08.008. Epub 2010 Sep 16.
5
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.更昔洛韦与马里巴韦交叉耐药性再探讨:典型巨细胞病毒突变体的相对药物敏感性
Antiviral Res. 2024 Feb;222:105792. doi: 10.1016/j.antiviral.2023.105792. Epub 2023 Dec 30.
6
Cytomegalovirus UL97 kinase mutations that confer maribavir resistance.巨细胞病毒UL97激酶突变导致对马立巴韦耐药。
J Infect Dis. 2007 Jul 1;196(1):91-4. doi: 10.1086/518514. Epub 2007 May 17.
7
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.巨细胞病毒 UL97 激酶序列变异体的重组表型分析与更昔洛韦耐药性的关系。
Antimicrob Agents Chemother. 2010 Jun;54(6):2371-8. doi: 10.1128/AAC.00186-10. Epub 2010 Apr 12.
8
Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.阿根廷免疫功能低下患者中与更昔洛韦耐药相关的巨细胞病毒UL97突变
J Clin Virol. 2004 Jul;30(3):271-5. doi: 10.1016/j.jcv.2003.11.003.
9
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.在一项关于马拉韦罗治疗耐药或难治性巨细胞病毒感染的临床试验中,基线时发现了新型 UL97 耐药突变。
Antiviral Res. 2019 Dec;172:104616. doi: 10.1016/j.antiviral.2019.104616. Epub 2019 Sep 27.
10
Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.由于UL97基因第595 - 596密码子处的联合缺失突变导致的耐更昔洛韦移植后巨细胞病毒感染。
Transpl Infect Dis. 2019 Dec;21(6):e13168. doi: 10.1111/tid.13168. Epub 2019 Sep 18.

引用本文的文献

1
Ganciclovir Resistance-Linked Mutations in the HCMV Gene: Sanger Sequencing Analysis in Samples from Transplant Recipients at a Tertiary Hospital in Southern Brazil.人巨细胞病毒基因中与更昔洛韦耐药相关的突变:巴西南部一家三级医院移植受者样本的桑格测序分析
Diagnostics (Basel). 2025 Jan 18;15(2):214. doi: 10.3390/diagnostics15020214.
2
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants.更昔洛韦与马里巴韦交叉耐药性再探讨:典型巨细胞病毒突变体的相对药物敏感性
Antiviral Res. 2024 Feb;222:105792. doi: 10.1016/j.antiviral.2023.105792. Epub 2023 Dec 30.
3
Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.巨细胞病毒 UL54 外切酶结构域突变对阿昔洛韦和更昔洛韦敏感性的相反影响。
Antiviral Res. 2021 Nov;195:105181. doi: 10.1016/j.antiviral.2021.105181. Epub 2021 Sep 21.
4
Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.巨细胞病毒抗病毒药物耐药性的基因诊断进展。
Antiviral Res. 2020 Apr;176:104711. doi: 10.1016/j.antiviral.2020.104711. Epub 2020 Jan 12.
5
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.血小板生成素受体激动剂艾曲波帕通过铁螯合抑制人巨细胞病毒复制。
Cells. 2019 Dec 20;9(1):31. doi: 10.3390/cells9010031.
6
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.造血干细胞移植受者巨细胞病毒预防的临床试验中的来特莫韦耐药分析。
J Infect Dis. 2020 Mar 16;221(7):1117-1126. doi: 10.1093/infdis/jiz577.
7
Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection.在一项关于马拉韦罗治疗耐药或难治性巨细胞病毒感染的临床试验中,基线时发现了新型 UL97 耐药突变。
Antiviral Res. 2019 Dec;172:104616. doi: 10.1016/j.antiviral.2019.104616. Epub 2019 Sep 27.
8
Patient-Derived Cytomegaloviruses with Different Ganciclovir Sensitivities from UL97 Mutation Retain Their Replication Efficiency and Some Kinase Activity .源自 UL97 基因突变的具有不同更昔洛韦敏感性的患者衍生巨细胞病毒保留其复制效率和部分激酶活性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.02425-18. Print 2019 Sep.
9
Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands.荷兰实体器官移植中抗病毒耐药的巨细胞病毒感染。
J Antimicrob Chemother. 2019 Aug 1;74(8):2370-2376. doi: 10.1093/jac/dkz196.
10
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials.移植受者中用于临床试验的耐更昔洛韦和难治性巨细胞病毒感染和疾病的定义。
Clin Infect Dis. 2019 Apr 8;68(8):1420-1426. doi: 10.1093/cid/ciy696.

本文引用的文献

1
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.映射到巨细胞病毒DNA聚合酶基因非典型结构域的膦甲酸耐药突变
Antiviral Res. 2017 Feb;138:57-60. doi: 10.1016/j.antiviral.2016.12.003. Epub 2016 Dec 8.
2
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.鉴定与耐药相关的人巨细胞病毒UL97和UL54突变以及一种对表型耐药有影响的UL97多态性。
Antiviral Res. 2016 Jul;131:1-8. doi: 10.1016/j.antiviral.2016.04.002. Epub 2016 Apr 4.
3
Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?成年肾移植受者中更昔洛韦的血浆和细胞内暴露情况:其与血液学毒性是否存在关联?
J Antimicrob Chemother. 2016 Feb;71(2):484-9. doi: 10.1093/jac/dkv342. Epub 2015 Nov 3.
4
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.导致来特莫韦耐药的人巨细胞病毒UL56突变的快速体外进化
Antimicrob Agents Chemother. 2015 Oct;59(10):6588-93. doi: 10.1128/AAC.01623-15. Epub 2015 Aug 10.
5
Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.采用改良的蚀斑减少试验鉴定新发现的与药物相关的 HCMV UL97 和 UL54 突变。
J Clin Virol. 2015 Aug;69:150-5. doi: 10.1016/j.jcv.2015.06.090. Epub 2015 Jun 19.
6
Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping.通过重组表型分析鉴定造血干细胞移植受者中多种巨细胞病毒药物耐药突变。
J Clin Microbiol. 2014 Nov;52(11):4043-6. doi: 10.1128/JCM.02205-14. Epub 2014 Aug 20.
7
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.人巨细胞病毒对更昔洛韦/缬更昔洛韦的耐药性:耐药途径的综合评价。
Antiviral Res. 2014 Jan;101:12-25. doi: 10.1016/j.antiviral.2013.10.011. Epub 2013 Oct 31.
8
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.更新的实体器官移植中巨细胞病毒管理的国际共识指南。
Transplantation. 2013 Aug 27;96(4):333-60. doi: 10.1097/TP.0b013e31829df29d.
9
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.巨细胞病毒 UL97 激酶催化结构域突变导致多药耐药。
Antimicrob Agents Chemother. 2013 Jul;57(7):3375-9. doi: 10.1128/AAC.00511-13. Epub 2013 May 6.
10
Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.使用高剂量更昔洛韦治疗诱导耐更昔洛韦的实体器官移植患者的巨细胞病毒复制。
Transplantation. 2013 Apr 27;95(8):1015-20. doi: 10.1097/TP.0b013e31828555ac.